That's a very optimistic view. BAL was too expensive for me at 1.8 and now I would consider that fair value.
No debt. minimal cash flow. no sales team. no manufacture. no distribution. Chinese customers might like it... but I don't think it even has a single digit percentage of market share. I don't think mead Johnson includes bellamys as a potential threat too it's market dominance in China.
The real issue is... how do you engage diagou after they just burnt them by undercutting their business. chemist warehouse wasnt keeping a list of the random students buying cans of step3. bellamys marketing director has no database of the large diagous. and it isn't legal to sell to them directly.
Am interesting puzzle.
I wonder how the new ceo and CFO will deal with this....
- Forums
- ASX - By Stock
- BAL
- Will go down hard after halt
Will go down hard after halt, page-20
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online